AICAR vs Tesofensine
A side-by-side research comparison of AICAR and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | Tesofensine |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 258.23 Da | 329.4 Da |
| Half-life | Short | 8-10 days |
| Bioavailability | Injection (research); poor oral | High (oral ~93%) |
| Typical dose | Not established for humans | 0.25-0.5 mg |
| Frequency | Research only | Once daily |
| Route | Injection (research) | Oral |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.